Caution Required for Healthcare Stocks in 2026
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1h ago
0mins
Should l Buy LLY?
Source: Fool
- High Valuations: While the healthcare sector's forward P/E is 18.7, Eli Lilly's forward P/E stands at 30.6, indicating excessive market optimism about its growth, thus increasing investment risks.
- Demand and Pressure: Healthcare demand remains relatively stable during economic slowdowns, but high inflation and slowing growth may lead to political pressures that could alter drug pricing and reimbursement policies, impacting revenues and earnings.
- Stability of Payment System: The U.S. healthcare payment system, comprising private insurance, public payers, and out-of-pocket spending, is not expected to change fundamentally in 2026; however, the implementation of drug price negotiations could pressure drugmakers' margins.
- Cautious Investment: Understanding how a business generates revenue and the potential legal or policy changes that could affect profitability is crucial for investors considering healthcare stocks, to avoid blindly following trends at market peaks.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy LLY?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on LLY
Wall Street analysts forecast LLY stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for LLY is 1192 USD with a low forecast of 950.00 USD and a high forecast of 1500 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
20 Analyst Rating
18 Buy
2 Hold
0 Sell
Strong Buy
Current: 1020.840
Low
950.00
Averages
1192
High
1500
Current: 1020.840
Low
950.00
Averages
1192
High
1500
About LLY
Eli Lilly and Company is a medicine company, which discovers, develops, manufactures, markets, and sells pharmaceutical products worldwide. Its cardiometabolic health products include Basaglar; Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, and others; Humulin, Humulin 70/30, and others; Jardiance; Mounjaro; Trulicity; Zepbound; VERVE-102; VERVE-201, and VERVE-301. Its oncology products include Cyramza, Erbitux, Tyvyt, and Verzenio. Its immunology products include Ebglyss, Olumiant, Omvoh, and Taltz. Its neuroscience products include Emgality and Kisunla. The Company is also engaged in radiopharmaceutical discovery, development, and manufacturing efforts, and clinical and pre-clinical radioligand therapies in development for the treatment of cancer. It is also developing an oral small molecule inhibitor of a4b7 integrin for inflammatory bowel disease (IBD). It is evaluating its novel gene therapy candidate, ixoberogene soroparvovec.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Eli Lilly Analyst Raises Price Target to $1,300
- Strong Earnings Beat: Eli Lilly reported sales of $19.292 billion and earnings of $7.54 per share, exceeding consensus estimates of $17.944 billion and $6.91 per share, indicating robust market performance and profitability.
- Sales Growth Highlights: Zepbound sales reached $4.261 billion, surpassing Street expectations of $3.880 billion, while Mounjaro sales stood at $7.409 billion, also beating the consensus of $6.820 billion, reflecting strong product demand.
- Optimistic Future Outlook: Management guided for 2026 sales of $80-$83 billion and earnings per share of $33.50-$35.00, higher than consensus estimates of $77.64 billion and $33.04, showcasing the company's growth potential.
- Prominent Growth Profile: The analyst noted that Eli Lilly has the best growth profile in their coverage universe, with projected top-line growth of approximately 20% and bottom-line growth of around 40% by 2026, establishing a clear runway for sustained growth into the next decade.
See More
Caution Required for Healthcare Stocks in 2026
- High Valuations: While the healthcare sector's forward P/E is 18.7, Eli Lilly's forward P/E stands at 30.6, indicating excessive market optimism about its growth, thus increasing investment risks.
- Demand and Pressure: Healthcare demand remains relatively stable during economic slowdowns, but high inflation and slowing growth may lead to political pressures that could alter drug pricing and reimbursement policies, impacting revenues and earnings.
- Stability of Payment System: The U.S. healthcare payment system, comprising private insurance, public payers, and out-of-pocket spending, is not expected to change fundamentally in 2026; however, the implementation of drug price negotiations could pressure drugmakers' margins.
- Cautious Investment: Understanding how a business generates revenue and the potential legal or policy changes that could affect profitability is crucial for investors considering healthcare stocks, to avoid blindly following trends at market peaks.
See More
S&P 500 Index Could Reach 15,000 by 2030
- Future Growth Outlook: Tom Lee from Fundstrat predicts that the S&P 500 index will reach 15,000 by 2030, implying a 120% upside from its current level of 6,830, presenting significant potential returns for investors.
- ETF Investment Advantage: The Vanguard S&P 500 ETF provides exposure to approximately 80% of U.S. equities and 50% of global equities by market value, offering broad access to many of the world's most influential stocks, particularly in the technology sector, enhancing portfolio diversity and potential returns.
- Strong Historical Performance: Over the past two decades, the S&P 500 has advanced 439%, compounding at an annual rate of 8.7%, and with dividends included, the total return reached 700%, compounding at 10.9%, demonstrating the wealth creation capability of long-term holding.
- Generational Wealth Transfer: Millennials are set to inherit $80 trillion and are reshaping the economy as they enter their peak earning years, combined with a predicted global labor shortage, which is expected to drive demand for technology stocks, further boosting the performance of the S&P 500 index.
See More
Novo Nordisk Shares Plunge 15% Post Earnings
- Post-Earnings Decline: Novo Nordisk's stock plummeted nearly 15% following its earnings report, with an additional 6% drop the next day, indicating significant market concern regarding its future performance.
- Sales Guidance Dismal: The company anticipates a sales hit of 5% to 13% this year, primarily due to intense pricing pressures in the GLP-1 market, particularly from competitors like Eli Lilly.
- Intensifying Market Competition: Cramer highlighted that while Novo Nordisk's quarterly results were decent, its competitive edge in the GLP-1 sector is being eroded by Eli Lilly, potentially leading to further market share loss.
- Cautious Investment Outlook: Cramer suggests that although Novo Nordisk has potential, it should be viewed as a hold rather than a buy, especially given Eli Lilly's strong performance, reflecting a cautious stance on future growth prospects.
See More
Walmart Joins Trillion-Dollar Market Cap Club
- New Trillion-Dollar Member: Walmart officially surpassed a $1 trillion market cap on February 3, becoming the 13th publicly traded company globally to reach this milestone, showcasing its strong competitive edge and market influence in the retail sector.
- Tech-Driven Growth: Walmart's push into online shopping and the Walmart+ subscription service led to a 27% increase in global e-commerce sales in the fiscal third quarter, enhancing customer experience and bolstering the company's long-term profitability.
- Potential Industry Leaders: JPMorgan Chase and Visa are seen as the next candidates for the trillion-dollar club, with market caps nearing $864 billion and $636 billion respectively, highlighting the stability and growth potential of the financial sector.
- Economic Cycle Challenges: While Walmart's success is notable, fluctuations in the economic cycle may pose challenges to the growth of JPMorgan Chase and Visa, prompting investors to carefully assess the market environment's impact on financial stocks.
See More
TrumpRx Launches, But Few Will Reap Its Benefits.
Limited Initial Benefits: Only a small segment of consumers is expected to benefit from the TrumpRx initiative aimed at reducing drug costs.
Expert Opinions: Experts suggest that the initiative may not provide widespread relief for all Americans regarding prescription drug prices.
See More
Eli Lilly Analyst Raises Price Target to $1,300
- Strong Earnings Beat: Eli Lilly reported sales of $19.292 billion and earnings of $7.54 per share, exceeding consensus estimates of $17.944 billion and $6.91 per share, indicating robust market performance and profitability.
- Sales Growth Highlights: Zepbound sales reached $4.261 billion, surpassing Street expectations of $3.880 billion, while Mounjaro sales stood at $7.409 billion, also beating the consensus of $6.820 billion, reflecting strong product demand.
- Optimistic Future Outlook: Management guided for 2026 sales of $80-$83 billion and earnings per share of $33.50-$35.00, higher than consensus estimates of $77.64 billion and $33.04, showcasing the company's growth potential.
- Prominent Growth Profile: The analyst noted that Eli Lilly has the best growth profile in their coverage universe, with projected top-line growth of approximately 20% and bottom-line growth of around 40% by 2026, establishing a clear runway for sustained growth into the next decade.
See More
Caution Required for Healthcare Stocks in 2026
- High Valuations: While the healthcare sector's forward P/E is 18.7, Eli Lilly's forward P/E stands at 30.6, indicating excessive market optimism about its growth, thus increasing investment risks.
- Demand and Pressure: Healthcare demand remains relatively stable during economic slowdowns, but high inflation and slowing growth may lead to political pressures that could alter drug pricing and reimbursement policies, impacting revenues and earnings.
- Stability of Payment System: The U.S. healthcare payment system, comprising private insurance, public payers, and out-of-pocket spending, is not expected to change fundamentally in 2026; however, the implementation of drug price negotiations could pressure drugmakers' margins.
- Cautious Investment: Understanding how a business generates revenue and the potential legal or policy changes that could affect profitability is crucial for investors considering healthcare stocks, to avoid blindly following trends at market peaks.
See More
S&P 500 Index Could Reach 15,000 by 2030
- Future Growth Outlook: Tom Lee from Fundstrat predicts that the S&P 500 index will reach 15,000 by 2030, implying a 120% upside from its current level of 6,830, presenting significant potential returns for investors.
- ETF Investment Advantage: The Vanguard S&P 500 ETF provides exposure to approximately 80% of U.S. equities and 50% of global equities by market value, offering broad access to many of the world's most influential stocks, particularly in the technology sector, enhancing portfolio diversity and potential returns.
- Strong Historical Performance: Over the past two decades, the S&P 500 has advanced 439%, compounding at an annual rate of 8.7%, and with dividends included, the total return reached 700%, compounding at 10.9%, demonstrating the wealth creation capability of long-term holding.
- Generational Wealth Transfer: Millennials are set to inherit $80 trillion and are reshaping the economy as they enter their peak earning years, combined with a predicted global labor shortage, which is expected to drive demand for technology stocks, further boosting the performance of the S&P 500 index.
See More
Novo Nordisk Shares Plunge 15% Post Earnings
- Post-Earnings Decline: Novo Nordisk's stock plummeted nearly 15% following its earnings report, with an additional 6% drop the next day, indicating significant market concern regarding its future performance.
- Sales Guidance Dismal: The company anticipates a sales hit of 5% to 13% this year, primarily due to intense pricing pressures in the GLP-1 market, particularly from competitors like Eli Lilly.
- Intensifying Market Competition: Cramer highlighted that while Novo Nordisk's quarterly results were decent, its competitive edge in the GLP-1 sector is being eroded by Eli Lilly, potentially leading to further market share loss.
- Cautious Investment Outlook: Cramer suggests that although Novo Nordisk has potential, it should be viewed as a hold rather than a buy, especially given Eli Lilly's strong performance, reflecting a cautious stance on future growth prospects.
See More
Walmart Joins Trillion-Dollar Market Cap Club
- New Trillion-Dollar Member: Walmart officially surpassed a $1 trillion market cap on February 3, becoming the 13th publicly traded company globally to reach this milestone, showcasing its strong competitive edge and market influence in the retail sector.
- Tech-Driven Growth: Walmart's push into online shopping and the Walmart+ subscription service led to a 27% increase in global e-commerce sales in the fiscal third quarter, enhancing customer experience and bolstering the company's long-term profitability.
- Potential Industry Leaders: JPMorgan Chase and Visa are seen as the next candidates for the trillion-dollar club, with market caps nearing $864 billion and $636 billion respectively, highlighting the stability and growth potential of the financial sector.
- Economic Cycle Challenges: While Walmart's success is notable, fluctuations in the economic cycle may pose challenges to the growth of JPMorgan Chase and Visa, prompting investors to carefully assess the market environment's impact on financial stocks.
See More
TrumpRx Launches, But Few Will Reap Its Benefits.
Limited Initial Benefits: Only a small segment of consumers is expected to benefit from the TrumpRx initiative aimed at reducing drug costs.
Expert Opinions: Experts suggest that the initiative may not provide widespread relief for all Americans regarding prescription drug prices.
See More
